DK2492355T3 - Vævsbeskyttende erythropoietinreceptor (nepor) samt anvendelsesfremgangsmåder - Google Patents
Vævsbeskyttende erythropoietinreceptor (nepor) samt anvendelsesfremgangsmåder Download PDFInfo
- Publication number
- DK2492355T3 DK2492355T3 DK11004689.3T DK11004689T DK2492355T3 DK 2492355 T3 DK2492355 T3 DK 2492355T3 DK 11004689 T DK11004689 T DK 11004689T DK 2492355 T3 DK2492355 T3 DK 2492355T3
- Authority
- DK
- Denmark
- Prior art keywords
- nepor
- disclosed
- erythropoietin
- tissue
- epo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/746—Erythropoetin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99104207P | 2007-11-29 | 2007-11-29 | |
| EP08854346A EP2109690B9 (en) | 2007-11-29 | 2008-11-28 | Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2492355T3 true DK2492355T3 (da) | 2015-07-13 |
Family
ID=40370571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11004689.3T DK2492355T3 (da) | 2007-11-29 | 2008-11-28 | Vævsbeskyttende erythropoietinreceptor (nepor) samt anvendelsesfremgangsmåder |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP2109690B9 (da) |
| AT (1) | ATE554186T1 (da) |
| AU (1) | AU2008328754B2 (da) |
| CA (2) | CA2706994C (da) |
| DK (1) | DK2492355T3 (da) |
| ES (2) | ES2386495T3 (da) |
| HR (1) | HRP20150733T1 (da) |
| HU (1) | HUE026591T2 (da) |
| PL (1) | PL2492355T3 (da) |
| PT (1) | PT2492355E (da) |
| SI (1) | SI2492355T1 (da) |
| WO (1) | WO2009068677A1 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339613B (es) | 2005-08-05 | 2016-06-02 | Araim Pharmaceuticals Inc | Peptidos protectores de tejido y sus usos. |
| PT2056845T (pt) | 2006-08-08 | 2017-11-17 | Rheinische Friedrich-Wilhelms-Universität Bonn | Estrutura e uso de oligonucleótidos com fosfato 5 |
| US8357501B2 (en) * | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
| JP5689413B2 (ja) | 2008-05-21 | 2015-03-25 | ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン | 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用 |
| EP2596125A1 (en) * | 2010-07-19 | 2013-05-29 | Cellzome Ag | In vivo method for the evaluation of a compound-target interaction |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| WO2012171996A1 (en) * | 2011-06-15 | 2012-12-20 | F. Hoffmann-La Roche Ag | Anti-human epo receptor antibodies and methods of use |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| SG11201600294QA (en) * | 2013-07-17 | 2016-02-26 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| WO2017134306A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Cd8 binding agents |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| EP3749295A4 (en) | 2018-02-05 | 2022-04-27 | Orionis Biosciences, Inc. | FIBROBLAST BINDING AGENTS AND USES THEREOF |
| CN111175519B (zh) * | 2020-01-09 | 2020-11-27 | 浙江大学 | Epo在制备肝细胞癌tace疗效评估试剂中的应用 |
| WO2022054748A1 (ja) * | 2020-09-10 | 2022-03-17 | 扶桑薬品工業株式会社 | エリスロポエチンシグナル伝達阻害タンパク質 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002951409A0 (en) * | 2002-09-16 | 2002-09-26 | North Western Adelaide Health Services | Methods for regulating cancer |
| JP4762889B2 (ja) * | 2003-03-12 | 2011-08-31 | バスジーン セラピューティクス，インコーポレイテッド | 血管形成及び腫瘍成長を阻止するための核酸化合物 |
| US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| US7718363B2 (en) * | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| EP1799867A2 (en) * | 2004-09-23 | 2007-06-27 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
-
2008
- 2008-11-28 HU HUE11004689A patent/HUE026591T2/hu unknown
- 2008-11-28 EP EP08854346A patent/EP2109690B9/en not_active Not-in-force
- 2008-11-28 PT PT110046893T patent/PT2492355E/pt unknown
- 2008-11-28 WO PCT/EP2008/066480 patent/WO2009068677A1/en active Application Filing
- 2008-11-28 EP EP11004689.3A patent/EP2492355B1/en not_active Not-in-force
- 2008-11-28 ES ES08854346T patent/ES2386495T3/es active Active
- 2008-11-28 AT AT08854346T patent/ATE554186T1/de active
- 2008-11-28 DK DK11004689.3T patent/DK2492355T3/da active
- 2008-11-28 CA CA2706994A patent/CA2706994C/en not_active Expired - Fee Related
- 2008-11-28 EP EP15000987.6A patent/EP2960341B1/en not_active Not-in-force
- 2008-11-28 ES ES11004689.3T patent/ES2542033T3/es active Active
- 2008-11-28 CA CA2802984A patent/CA2802984C/en not_active Expired - Fee Related
- 2008-11-28 AU AU2008328754A patent/AU2008328754B2/en not_active Ceased
- 2008-11-28 PL PL11004689T patent/PL2492355T3/pl unknown
- 2008-11-28 SI SI200831453T patent/SI2492355T1/sl unknown
-
2015
- 2015-07-06 HR HRP20150733TT patent/HRP20150733T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2386495T3 (es) | 2012-08-21 |
| EP2492355B1 (en) | 2015-04-08 |
| CA2802984C (en) | 2016-04-12 |
| SI2492355T1 (sl) | 2015-08-31 |
| EP2960341A1 (en) | 2015-12-30 |
| HRP20150733T1 (hr) | 2015-08-14 |
| CA2802984A1 (en) | 2009-06-04 |
| AU2008328754A1 (en) | 2009-06-04 |
| CA2706994C (en) | 2013-03-12 |
| ATE554186T1 (de) | 2012-05-15 |
| CA2706994A1 (en) | 2009-06-04 |
| EP2492355A1 (en) | 2012-08-29 |
| WO2009068677A1 (en) | 2009-06-04 |
| EP2960341B1 (en) | 2018-06-27 |
| HUE026591T2 (hu) | 2016-06-28 |
| ES2542033T3 (es) | 2015-07-29 |
| EP2109690A1 (en) | 2009-10-21 |
| EP2109690B1 (en) | 2012-04-18 |
| AU2008328754B2 (en) | 2015-04-16 |
| EP2109690B9 (en) | 2012-10-24 |
| PL2492355T3 (pl) | 2015-09-30 |
| PT2492355E (pt) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2492355T3 (da) | Vævsbeskyttende erythropoietinreceptor (nepor) samt anvendelsesfremgangsmåder | |
| MX2020000604A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| EP2531598A4 (en) | WHSC1 AND WHSC1L1 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS | |
| EA200971079A1 (ru) | ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ | |
| Buess et al. | Tumor-Endothelial interaction links the CD44+/CD24-phenotype with poor prognosis in early-stage breast cancer | |
| Cashman et al. | SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade | |
| WO2014057357A3 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf | |
| WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
| WO2005083086A3 (en) | Epha4 as therapeutic target of prc and pdaca | |
| Yang et al. | The expression and related clinical significance of SIRT3 in non-small-cell lung cancer | |
| MXPA05014220A (es) | Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos. | |
| Paschke et al. | ZFP91: A noncanonical NF-κB signaling pathway regulator with oncogenic properties is overexpressed in prostate cancer | |
| GB2523211A8 (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| Wang et al. | Single-cell RNA sequencing analysis dissected the osteo-immunology microenvironment and revealed key regulators in osteoporosis | |
| Winter et al. | Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status | |
| Yuan et al. | miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2 | |
| Coelho et al. | Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC | |
| Iacobas et al. | Towards a personalized cancer gene therapy: a case of clear cell renal cell carcinoma | |
| Wu et al. | Protein phosphatase 2A regulatory subunit B56β modulates erythroid differentiation | |
| WO2017053763A3 (en) | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) | |
| WO2007050798A3 (en) | Lrrtm1 compositions and methods of their use for the diagnosis and treatment of cancer | |
| Yong et al. | Decreased expression of miR-132 in CRC tissues and its inhibitory function on tumor progression | |
| Yashaswini et al. | Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease | |
| Yue et al. | Expression of DLK1 gene in the bone marrow cells of patients with myelodysplastic syndromes and its clinical significance | |
| Zhiqiang et al. | Abnormal expressed long non-coding RNA IRAIN inhibits tumor progression in human renal cell carcinoma cells |